Bernstein Liebhard LLP, a nationwide law firm representing clients who have filed Fosamax femur fracture lawsuits, reports that this group of lawsuits against Merck, the manufacturer of the widely prescribed osteoporotic drug, is moving towards trial. On June 4, 2012, the Honorable Carol E. Higbee, who is overseeing In re: Fosamax Litigation (No. 282 N.J. Super Ct.), a mass tort action currently pending in the Superior Court of New Jersey, Atlantic County, sent a letter to counsel representing clients in the Fosamax lawsuits against Merck, informing them that she intends to focus on the trials of the bellwether cases involving Fosamax femur fractures. Because the side effects of Fosamax include femur fractures and osteonecrosis of the jaw (“ONJ”), plaintiffs have filed lawsuits against Merck alleging different injuries. However, both the ONJ and Fosamax femur fracture lawsuits have been consolidated into one mass tort action in New Jersey state court. The first New Jersey state court case to go to trial, Jo Ann Sessner v. Merck, involved a plaintiff suffering from ONJ and resulted in a defense verdict. Originally, Judge Higbee intended to try another case involving ONJ. According to the June 4th letter, she has instead decided to move forward with a trial involving a femur fracture injury.

“Our clients are excited to see that the Court and the parties are now focusing on femur fracture injuries and look forward to resolution of their claims at trial,” commented Bernstein Liebhard LLP Partner Jeffrey S. Grand.

Fosamax Femur Fracture Lawsuits Against Merck

The lawyers at Bernstein Liebhard LLP are currently representing clients and actively filing cases on behalf of individuals who were allegedly injured as a result of taking Fosamax. Those who took Fosamax and sustained a femur fracture may be entitled to compensation for medical bills, pain and suffering, lost wages and other injuries. Learn more by watching this Fosamax femur fracture video, which details the events leading up to the Fosamax lawsuits against Merck.

In October 2010, the U.S. Food and Drug Administration issued a Fosamax warning that Fosamax and other bisphosphonates put patients at risk for atypical thigh bone (femur) fractures. Since that time, Bernstein Liebhard LLP has provided a wealth of consumer information concerning the risks associated with Fosamax use on its website,

About Bernstein Liebhard LLP

Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993, including those who have been harmed by dangerous drugs, defective medical devices and consumer products. The firm has been named by The National Law Journal to the “Plaintiffs’ Hot List,” recognizing the top plaintiffs’ firms in the country, for the past nine consecutive years. Only two firms in the country have been selected for the Hot List nine years in a row.

Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016
(877) 779-1414

ATTORNEY ADVERTISING. © 2012 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, (212) 779-1414. The lawyer responsible for this advertisement in the State of Connecticut is Amy L. Abate.  Prior results do not guarantee or predict a similar outcome with respect to any future matter.

Contact Information:
Felecia L. Stern, Esq.
Bernstein Liebhard LLP

Published June 8, 2012 by